Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
Crossref DOI link: https://doi.org/10.1007/s00280-016-3203-7
Published Online: 2016-11-22
Published Print: 2017-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nakamura, Masato
Aoyama, Toru
Ishibashi, Keiichiro
Tsuji, Akihito
Takinishi, Yasutaka
Shindo, Yoshiaki
Sakamoto, Junichi
Oba, Koji
Mishima, Hideyuki
License valid from 2016-11-22